COMP <GO>
ALNY vs INSM // FORWARD P/E MULTIPLE
Alnylam Pharmaceuticals Inc. (NASDAQ) VS. Insmed Incorporated (NASDAQ) • 15-METRIC TALLY: ALNY 6
— INSM 6
▲ FORWARD P/E MULTIPLE LEADER: INSM
LAST: $158.00 (-4.24%) • MKT CAP: $22.10B
forward-pe
62.3x
LAST: $109.31 (-2.90%) • MKT CAP: $24.70B
forward-pe
21.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALNY VS. INSM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALNY | INSM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 81.80% | 79.70% | +2.10 | ALNY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.30% | -35.00% | +56.30 | ALNY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 42.4x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.00% | -3.97% | +5.97 | ALNY | /fcf-yield <GO> |
| Operating Margin | 13.50% | -60.00% | +73.50 | ALNY | /operating-margins <GO> |
| Net Profit Margin | 8.40% | -60.00% | +68.40 | ALNY | /net-margins <GO> |
| Revenue Growth (YoY) | 65.20% | 66.70% | -1.50 | INSM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.16 | 5.25 | -2.09 | INSM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | ALNY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 25.8 | 62.2 | -36.40 | INSM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.03 | -0.03 | INSM | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 62.3x | 21.0x | +41.30 | INSM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $22.10B | $24.70B | -$2.60B | INSM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALNY REV | INSM REV | ALNY GROSS % | INSM GROSS % | ALNY FCF | INSM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.71B | $606.4M | 81.8% | 79.7% | $465.4M | -$967.6M |
| FY 2024 | $2.25B | $363.7M | 86.4% | 76.4% | -$42.6M | -$705.8M |
| FY 2023 | $1.83B | $305.2M | — | — | $21.9M | -$550.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALNY // BETA 1.00
INSM // BETA 1.03